<DOC>
	<DOCNO>NCT02541591</DOCNO>
	<brief_summary>The primary objective Neuroprotect trial ass whether new goal direct hemodynamic optimization strategy reduce cerebral ischemia post-cardiac arrest ( CA ) patient .</brief_summary>
	<brief_title>Neuroprotective Goal Directed Hemodynamic Optimization Post-cardiac Arrest Patients</brief_title>
	<detailed_description>Unconscious patient admit intensive care unit successfully resuscitate cardiac arrest ( CA ) high risk death , neurological deficit common among survivor . Nevertheless , optimal hemodynamic strategy ensure optimal cerebral perfusion maximal outcome study randomize controlled trial . In absence good evidence , current post-CA guideline adapt sepsis guideline recommend target mean arterial pressure ( MAP ) 65 mmHg ( Peberdy ea , Circulation 2010 ) . Importantly , post-CA patient large cerebral penumbra risk infarction resuscitate suboptimal MAP 's . In large subset post-CA patient low threshold cerebral autoregulation shift rightward patient might benefit resuscitation high MAP 's ( Sundgreen ea , Stroke 2001 ) order ensure adequate cerebral oxygenation . Our research group previously show MAP 85-100mmHg result optimal cerebral perfusion post-CA patient ( Ameloot ea , resuscitation 2015 ) . Two retrospective 2 prospective observational study suggest association high MAP 's good outcome post-CA patient ( Ameloot ea , resuscitation 2015 ) . However , value trial limit observational design . The question remain whether patient high MAP 's good outcome due optimal cerebral perfusion less cerebral damage whether high MAP merely non-causal marker limit disease severity patient . In word , primary research question whether reduce cerebral ischemia improve prognosis post-cardiac arrest survivor target high mean systemic blood pressure thereby optimize cerebral perfusion stay intensive care unit . To answer , propose multicenter interventional open label investigator drive randomize controlled trial compare goal-directed potentially neuro-protective hemodynamic optimization strategy current standard care . Primary efficacy endpoint study include extent cerebral damage assess diffusion weight magnetic resonance imaging ( DW-MRI ) , functional neurocognitive testing , biomarkers brain injury survival rate . The final utilization goal Neuroprotect post-CA trial show adapt hemodynamic protocol reduces cerebral ischemia , improve survival functional outcome post-cardiac arrest patient .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Heart Arrest</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>1 . Outofhospital CA presume cardiac cause irrespective presenting rhythm 2 . Unconsciousness ( Glasgow coma scale &lt; 8 ) hospital admission 3 . Age â‰¥ 18 year 4 . Sustained return spontaneous circulation ( ROSC ) ( =when chest compression require 20 consecutive minute ) 1 . Suspected confirmed intracranial bleeding stroke 2 . Known limitation therapy Do Not Resuscitateorder 3 . Known disease compromise 180 day survival 4 . Known preCA cerebral performance category 34 5 . Previous stroke ( TIA include ) 6 . MRI incompatible cardiac neurosurgical device 7 . Systolic blood pressure &lt; 90 mmHg norepinephrine &gt; 1 mcg/kg/min ) . 8 . Open chest 9 . ECMO ( extracorporeal membrane oxygenation ) 10 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>post cardiac arrest</keyword>
	<keyword>hemodynamics</keyword>
</DOC>